Exelixis Abandons Tissue Factor-Targeting ADC Due to Competition from Tivdak

Exelixis Decision::
Exelixis has decided to discontinue its tissue factor-targeting antibody-drug conjugate (ADC) due to concerns that it would not be competitive against Pfizer and Genmab's Tivdak.

Reason for Discontinuation::
The decision was made after concluding that the ADC candidate was unlikely to outperform Tivdak, a drug already established in the market.

Impact on Biotech Industry::
This move reflects the competitive landscape in the biotech industry, where companies must continually assess the viability of their drug candidates against existing treatments.

Tivdak Dominance::
Tivdak's strong market presence and efficacy have made it a benchmark for new ADCs, influencing Exelixis's decision to halt development of its own ADC.

Future Directions::
Exelixis may redirect resources to other promising drug candidates or research areas to maintain its competitive edge in the biotech sector.